Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Bispecific CAR-T in R/R B-Cell Lymphoma
NCT03881761Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2019
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) in B cell lymphoma, sponsored by Henan Cancer Hospital. Primary endpoint: Occurrence of study related adverse events at 1 year. Status: unknown.
02
Drugs
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital)
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03881761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881761.